TWiPO #26 ~ Killer Immunoglobulin Receptor (KIR) Mismatch in Neuroblastoma

May 07, 2012

In this interesting episode, host Dr. Tim Cripe (Nationwide Children's) and co-hosts Dr. Lionel Chow (Cincinnati Children's), Dr. Andy Kolb (AI DuPont), and Donna Ludwinski (Solving Kids' Cancer) quiz Dr Paul Sondel and Dr. Ken DeSantes (both from University of Wisconsin - Madison) on NK cells and the implications of KIR/KIR-ligand mismatch (killer immunoglobulin-like receptor) with regard to immunotherapy treatment of neuroblastoma.

References:

Delgado DC, Hank JA, Kolesar J, Lorentzen D, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 1;70(23):9554-61. Epub 2010 Oct 8. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999644/

.

Venstrom JM, Zheng J, Noor N, Danis KE, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009 Dec 1;15(23):7330-4. Epub 2009 Nov 24. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788079/

.

Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011;2011:379123. Epub 2011 May 24. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110303/